Table 1

Study procedures. Visit 1 (day 0): Screening visit; Visit 2 (week 1): Nurse visit; Visit 3 (week 4): Nurse visit; Visit 4 (week 8): Physician and nurse visit; Visit 5 (week 20): Physician and nurse visit; Visit 6 (week 32): Final visit; Physician and nurse visit

Visit numberVisit 1Visit 2Visit 3Visit 4Visit 5Visit 6
Visit typeNurseNurseNurseNurse and  physicianNurse and physicianNurse and physician
TimelineDay 0Week 1Week 4Week 8Week 20Week 32
Study procedures
Informed consentX
Inclusion/exclusion criteriaX
RandomisationX
DemographicsX
Medical/asthma historyX
Concomitant medicationsXXXXXX
Physician reviewXXX
Weight and heightX
Bloods: IgEX
Bloods: RAST IgEX
Bloods: PAXgeneXX
Bloods: eosinophil count and periostinXXXXXX
FeNOXXXXXX
Dispense home FeNO monitorX
Retrieve home FeNO monitorX
Dispense fluticasone with INCATM deviceX
Retrieve fluticasone with INCATM deviceX
PEFRXXXXXX
SpirometryXXXXX
AQLQ, ACT and EQ-5D-3LXXXXX
WPAI (Asthma)XXXXXX
Dispense peak flow meterXXXXXX
Perform IPS (Visit 1 both groups, Visit 4 control only)XX
Review peak flow readings (active only)XXXXX
Dispense INCATM with salmeterol/fluticasoneXXXX
Dispense INCATM with salbutamol (if required)XXXXX
INCATM download and feedback (active only)X (fluticasone) XXXX
Record any adverse eventsXXXXX
Exacerbations and healthcare utilisationXXXXXX
Asthma management planXXXXX
Dispense prescription for inhaler without INCATM deviceX
  • ACT, asthma control test; AQLQ, Asthma Quality of Life Questionnaire; FeNO, Ffractional Eexhaled Nnitric Ooxide; INCATM, Inhaler Compliance Assessment; IPS, Inhaler Proficiency check-list Score; PEFR, peak expiratory flow rate; RAST, radioallergosorbent test; WPAI, Work Productivity and Activity Impairment.